MEDP vs. SYNH, CRL, INCY, ICLR, OGN, ROIV, BLCO, TXG, OPCH, and LNTH
Should you be buying Medpace stock or one of its competitors? The main competitors of Medpace include Syneos Health (SYNH), Charles River Laboratories International (CRL), Incyte (INCY), ICON Public (ICLR), Organon & Co. (OGN), Roivant Sciences (ROIV), Bausch + Lomb (BLCO), 10x Genomics (TXG), Option Care Health (OPCH), and Lantheus (LNTH). These companies are all part of the "medical" sector.
Medpace vs.
Syneos Health (NASDAQ:SYNH) and Medpace (NASDAQ:MEDP) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, community ranking, analyst recommendations and earnings.
Syneos Health presently has a consensus price target of $54.00, indicating a potential upside of 57.30%. Medpace has a consensus price target of $235.50, indicating a potential upside of 29.74%. Given Syneos Health's higher possible upside, equities research analysts clearly believe Syneos Health is more favorable than Medpace.
93.5% of Syneos Health shares are owned by institutional investors. Comparatively, 82.5% of Medpace shares are owned by institutional investors. 0.3% of Syneos Health shares are owned by insiders. Comparatively, 20.6% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, Syneos Health had 1 more articles in the media than Medpace. MarketBeat recorded 9 mentions for Syneos Health and 8 mentions for Medpace. Syneos Health's average media sentiment score of 1.08 beat Medpace's score of 0.39 indicating that Syneos Health is being referred to more favorably in the media.
Syneos Health has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500. Comparatively, Medpace has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.
Syneos Health has higher revenue and earnings than Medpace. Syneos Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.
Syneos Health received 227 more outperform votes than Medpace when rated by MarketBeat users. Likewise, 68.89% of users gave Syneos Health an outperform vote while only 64.39% of users gave Medpace an outperform vote.
Medpace has a net margin of 16.81% compared to Syneos Health's net margin of 4.94%. Medpace's return on equity of 60.42% beat Syneos Health's return on equity.
Summary
Syneos Health beats Medpace on 10 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MEDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
